Acumen Pharmaceuticals Inc
ABOS
Get informed when a big investor buys or sells
+ FollowMarket Cap$191.4M
Close$
$0.37
85.9% downside
Current Fair Value
85.9% downsideOvervalued by 85.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $191.40 Million |
|---|---|
| Enterprise Value | $163.53 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2 |
| Beta | 0.33 |
| Outstanding Shares | 72,250,694 |
Return
| Return on Equity | -183.44% |
|---|---|
| Return on Assets | -90.55% |
| Return on Invested Capital | -149.45% |
Valuation & Multiples
| P/E Ratio | -1.62 |
|---|---|
| PEG | 8.04 |
| Price to Sales | -2.65 |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | -1816.99 |
| Enterprise Value to EBIT | -1.58 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.19 |
| Debt to Equity | 0.55 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 17, 2026
EPS Estimate
$-0.35
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 11, 2026
EPS Estimate
$-0.43
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 108.91% |
|---|---|
| Total Calls | 59,400▼ 25.47% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 66.40%▼ 6.37% |
|---|---|
| Total Invested | $128.08M▲ 18.01% |
| Investors Holding | 99▲ 10.00% |
ESG Score
No data
About Acumen Pharmaceuticals Inc
2,021 employees